Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish pharma ...
Abstract: This paper presents a comprehensive fault identification technique for a single-phase matrix converter (SPMC) based boost rectifier circuit. The primary objective of the fault identification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results